GSA Capital Partners LLP Takes $539,000 Position in Halozyme Therapeutics, Inc. $HALO

Posted by Brenda Bartman on Aug 21st, 2026

GSA Capital Partners LLP purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) during the 2nd quarter, HoldingsChannel reports. The institutional investor purchased 6,883 shares of the biopharmaceutical company’s stock, valued at approximately $539,000.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Empowered Funds LLC acquired a new stake in Halozyme Therapeutics in the 1st quarter valued at about $755,000. Acadian Asset Management LLC acquired a new position in shares of Halozyme Therapeutics during the first quarter worth approximately $195,000. Hsbc Holdings PLC lifted its position in shares of Halozyme Therapeutics by 117.1% during the second quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock worth $522,000 after purchasing an additional 5,448 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Halozyme Therapeutics by 6.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 174 shares during the last quarter. Finally, Baird Financial Group Inc. grew its stake in shares of Halozyme Therapeutics by 6.2% during the second quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock valued at $577,000 after purchasing an additional 650 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $106.12 on Friday. The stock has a market cap of $12.04 billion, a PE ratio of 31.68, a price-to-earnings-growth ratio of 0.43 and a beta of 0.85. The stock has a 50-day moving average of $82.42 and a 200-day moving average of $73.50. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. Halozyme Therapeutics, Inc. has a one year low of $61.22 and a one year high of $107.96.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm had revenue of $481.00 million during the quarter, compared to analysts’ expectations of $402.28 million. During the same quarter in the previous year, the company earned $1.54 earnings per share. The business’s revenue for the quarter was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current year.

Insider Activity

In related news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00. Following the completion of the sale, the chief executive officer owned 767,780 shares in the company, valued at $79,987,320.40. This represents a 2.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the transaction, the director owned 14,462 shares in the company, valued at approximately $1,084,650. This represents a 33.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 64,103 shares of company stock valued at $5,226,496 in the last quarter. Company insiders own 2.50% of the company’s stock.

Analyst Ratings Changes

HALO has been the topic of a number of recent research reports. HC Wainwright increased their price objective on Halozyme Therapeutics from $95.00 to $115.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. TD Cowen raised their price target on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a report on Friday, August 7th. Leerink Partners upgraded Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $83.00 to $110.00 in a research report on Friday, August 7th. Finally, UBS Group reissued a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Nine research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $91.20.

Read Our Latest Report on HALO

About Halozyme Therapeutics

(Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.